Aduhelm News Today

Panelists at the leading health economics and outcomes conference discuss whether the FDA's process for allowing outside experts to weigh in on drug approvals needs changes.

Skepticism may be warranted when Medicare says it expects to spend $3.5 billion on the Alzheimer’s disease drug Leqembi.

Readers discuss a column by David Brooks. Also: Tears for America; the border reform bill; FAFSA delays; an Alzheimer’s drug; protests in Israel.

Biogen Inc.’s problematic trip with Aduhelm (aducanumab-avwa) for Alzheimer’s disease at last came to an end as the company, probably surprising few on Wall Street, said it’s quitting sales and development of the amyloid-beta directed antibody. The drug won accelerated approval by the U.S. FDA in July 2021.

Biogen announced Wednesday that it is stopping its clinical trials of an Alzheimer's drug, will no longer sell it, and is forsaking the ownership rights. Along with federal...

Aduhelm is being discontinued by drugmaker Biogen as it shifts resources to its other Alzheimer's medication, Leqembi, and developing other treatments.

Biogen announced it will discontinue marketing the Alzheimer’s drug Aduhelm. This ends the tortuous saga of a once-promising treatment for the memory-robbing disease.

The FDA approved Biogen's $56,000 anti-amyloid drug in 2021, against the advice of outside experts.

A controversial Alzheimer's drug that was trumpeted as the first to ever treat the cognitive decline associated with the devastating brain disorder has been pulled from the market, its maker Biogen announced Wednesday. It showed a reduction in cognitive decline in one of the studies, but not the other.

Biogen has returned its Aduhelm rights to Neurimmune, the company that initially developed the antibody Alzheimer’s disease drug. But Biogen isn’t abandoning Alzheimer’s, and its pipeline includes drugs that take other approaches to the neurodegenerative disorder.